Chantix Success Rate: The Real Numbers Behind Varenicline

Everyone wants to know the same thing. “If I take Chantix, what are my chances of actually quitting?” Fair question. You’re considering a prescription medication with real side effects and real costs. You deserve real numbers, not marketing copy.

I’m going to give you the clinical trial data, the real-world data, the long-term data, and the combination therapy data. Then I’m going to tell you what these numbers actually mean for your individual quit attempt, because statistics and individual outcomes are two very different things.

The Headline Clinical Trial Numbers

The pivotal Phase III trials for varenicline established the numbers that you’ll see quoted most often.

12-week continuous abstinence rate (end of treatment):

Varenicline 1 mg twice daily: approximately 44%
Bupropion 150 mg twice daily: approximately 24%
Placebo: approximately 18%

These come from the Jorenby et al. (2006) and Gonzales et al. (2006) studies, published in JAMA, which were the trials that led to FDA approval. The studies were randomized, double-blind, and placebo-controlled. Standard gold-standard methodology.

That 44% number means that out of every 100 people who took varenicline as directed for 12 weeks, about 44 were not smoking at the end of treatment. Compared to about 18 out of 100 who quit with a sugar pill and willpower. Varenicline roughly 2.5x’d the quit rate.

The EAGLES Trial Numbers

The EAGLES trial (2016) was even larger and more important because it directly compared varenicline to other active treatments, not just placebo.

Continuous abstinence, weeks 9-12:

Varenicline: 25.5% (non-psychiatric cohort) to 18.3% (psychiatric cohort)
Bupropion: 18.8% (non-psychiatric) to 13.7% (psychiatric)
Nicotine patch: 18.5% (non-psychiatric) to 13.0% (psychiatric)
Placebo: 11.8% (non-psychiatric) to 8.3% (psychiatric)

Wait, those numbers look lower than the pivotal trials. That’s because EAGLES measured a different time window (weeks 9-12 continuous abstinence vs. the full 12-week period) and had a more diverse, real-world population. The relative differences between treatments are what matter, and they’re consistent: varenicline outperformed everything else.

Note that even in the psychiatric cohort, people with diagnosed mental health conditions, varenicline was still the most effective option. This is important because people with psychiatric conditions smoke at much higher rates and are often denied varenicline due to lingering concerns about the (now removed) black box warning.

The 6-Month Numbers

Here’s where enthusiasm starts to meet reality. Quitting for 12 weeks while you’re on medication is one thing. Staying quit after you stop the drug is the real test.

At 6 months (about 3 months after ending a standard 12-week course):

Varenicline users: approximately 30-33% still abstinent
Bupropion users: approximately 20-22% still abstinent
Nicotine patch users: approximately 18-20% still abstinent
Placebo: approximately 12-15% still abstinent

You lose roughly a quarter to a third of quitters between the end of treatment and the 6-month mark. This happens with every cessation method. The transition off medication is a vulnerable period, and relapse rates are highest in the first few months after stopping pharmacotherapy.

The 12-Month Numbers

At one year, the numbers thin out further:

Varenicline users: approximately 22-25% still abstinent
Bupropion users: approximately 15-18% still abstinent
Nicotine patch users: approximately 14-17% still abstinent
Placebo/cold turkey: approximately 5-8% still abstinent

So roughly one in four people who take a full course of varenicline are still smoke-free a year later. That might sound discouraging at first. But consider the baseline. Without any treatment, long-term quit rates for unassisted attempts are somewhere around 3-5%. Varenicline increases your odds by roughly 5 to 7 times compared to just deciding to quit one day.

Extended Therapy Numbers

What if you take it for longer than 12 weeks?

Tonstad et al. (2006) studied an additional 12 weeks of varenicline (24 weeks total) in people who had successfully quit during the initial 12-week course. The results were significant:

At the end of the extended treatment (week 24): 70.5% of the extended varenicline group maintained abstinence vs. 49.6% on placebo.
At week 52 (6 months after stopping extended treatment): 44% of the extended treatment group was still abstinent vs. 37% in the group that only received 12 weeks.

The extended course clearly helps. If you’ve quit successfully at 12 weeks, continuing for another 12 weeks provides a real buffer against relapse. Many doctors now routinely offer the extended course, especially for patients with a strong history of relapse.

Combination Therapy Numbers

Can you boost varenicline’s effectiveness by combining it with other treatments?

Varenicline + Nicotine Patch

A 2014 study published in JAMA (Koegelenberg et al.) found that combining varenicline with a 21 mg nicotine patch for the first 12 weeks produced significantly higher quit rates than varenicline alone:

Varenicline + patch: 49% at 12 weeks
Varenicline + placebo patch: 33% at 12 weeks

At 6 months, the combination group still maintained an advantage (65% vs. 47% among those who initially quit). The combination was well-tolerated, with no significant increase in adverse events.

Varenicline + Behavioral Counseling

Adding structured behavioral support (whether in-person counseling, phone counseling, or digital programs) consistently improves quit rates across all cessation methods, including varenicline.

Studies show that varenicline combined with intensive behavioral support can achieve 12-week quit rates in the 50-60% range. The more support, the better the numbers. This is true for every cessation method, so it doesn’t change the relative ranking, but it does push the absolute numbers higher.

Varenicline + Bupropion

Some research has looked at combining varenicline with bupropion. A 2018 study found a modest additional benefit, but the evidence is less robust than for the varenicline + patch combination. Side effects increase with combination use. Most clinicians consider this a second-line combination.

Real-World vs. Clinical Trial Performance

All the numbers above come from clinical trials, and clinical trial participants are not typical smokers. They’re motivated enough to enroll in a study, they receive regular follow-up and support, they’re monitored for compliance, and they know they’re being observed (which itself changes behavior).

Real-world effectiveness studies paint a different picture. Observational data from healthcare systems and pharmacy claims databases generally show:

12-week quit rates: 25-35% (vs. ~44% in trials)
12-month quit rates: 15-20% (vs. ~22-25% in trials)

The gap isn’t as large as you might expect, which speaks to varenicline’s robustness. It still works in the messy real world, just not quite as well as it does in the controlled environment of a clinical trial. Part of this gap is adherence. In trials, compliance is monitored. In the real world, people miss doses, stop early because of side effects, or never fill the prescription at all.

What These Numbers Mean for You Personally

Statistics describe populations, not individuals. Your personal outcome with varenicline will depend on factors that clinical trials can’t fully capture:

Factors that improve your odds:

Taking the full 12-week course (or better, 24 weeks)
Taking every dose as prescribed, with food
Combining with behavioral support (counseling, quitline, support group)
Having a strong personal reason to quit
Having a supportive environment (partner who doesn’t smoke, smoke-free workplace)
Removing smoking cues from your environment
Using the extended 24-week course if your doctor offers it

Factors that lower your odds:

Stopping the medication early due to side effects
Not taking it consistently (missing doses)
High alcohol consumption (associated with relapse)
Living with other smokers
High stress levels without coping strategies
No behavioral support at all
History of multiple failed quit attempts (though this is somewhat offset by the fact that many successful quitters needed multiple attempts)

How Chantix Compares to Everything Else

For context, here’s a broader comparison of 12-month continuous abstinence rates from meta-analyses and large trials:

Method	~12-Month Quit Rate
Varenicline (12 weeks)	22-25%
Varenicline (24 weeks)	30-35%
Varenicline + NRT patch	28-32%
Combination NRT (patch + gum/lozenge)	15-20%
Bupropion	15-18%
Nicotine patch alone	14-17%
Nicotine gum alone	12-16%
Cold turkey (no support)	3-5%

Varenicline is at the top of every comparison, whether you’re looking at short-term or long-term numbers. The gap narrows somewhat at the 12-month mark (because relapse affects all groups), but it’s consistently the leader.

The Number That Matters Most

Here’s the number I keep coming back to. If you smoke a pack a day from age 20, you have roughly a 50% chance of dying from a smoking-related disease. That’s the real statistic to compare everything against.

A 22-25% chance of being quit at one year, with the option to try again if you relapse, is not a coin flip. It’s not a guarantee. But it’s the best shot available with any single medication, and it’s dramatically better than the alternative.

Most successful former smokers tried multiple times before it stuck. The average is somewhere around 8-11 attempts. Each attempt with an effective medication like varenicline gives you better odds than going without. And every attempt teaches you something about your patterns, your triggers, and what works for you.

The question isn’t whether 25% is high enough. The question is whether you’d take a 1-in-4 chance if the prize was living 10 years longer. Because that’s roughly what we’re talking about.

The Practical Takeaway

If you’re considering Chantix/varenicline, here’s what the data says you should do to maximize your odds:

Get the prescription and commit to taking the full course. Don’t stop at 8 weeks because you feel good.
Ask about the extended 24-week course. The data supports it.
Take every dose with food, on schedule.
Add behavioral support. Call 1-800-QUIT-NOW, use a cessation app, see a counselor, join an online community. Anything.
Ask your doctor about adding a nicotine patch, especially if you smoke more than a pack a day.
If you relapse, try again. Each attempt isn’t a failure. It’s training.

The numbers are on your side. Not overwhelmingly, but meaningfully. And in a fight against nicotine addiction, meaningful is enough to work with.